Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy
Phase 1
Terminated
- Conditions
- Tumors That Express CA 19-9Pancreatic Carcinoma
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- BioNTech Research & Development, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03118349
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸MSKCC, New York, New York, United States
Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1
Phase 1
Terminated
- Conditions
- Pancreatic CarcinomaTumors That Express CA19-9
- Interventions
- First Posted Date
- 2016-02-22
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- BioNTech Research & Development, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02687230
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
Phase 1
Terminated
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- BioNTech Research & Development, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT02672917
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸The Angeles Clinic & Research Institute, Los Angeles, California, United States
🇺🇸Florida Cancer Specialist and Research Institute, Sarasota, Florida, United States
News
No news found